CVRx Inc
NASDAQ:CVRX
CVRx Inc
Research & Development
CVRx Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
CVRx Inc
NASDAQ:CVRX
|
Research & Development
-$11.1m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Research & Development
-$2.1B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-9%
|
|
|
Stryker Corp
NYSE:SYK
|
Research & Development
-$1.6B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-10%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Research & Development
-$2.9B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-8%
|
|
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
Research & Development
-$251.2m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-10%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Research & Development
-$1.3B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-21%
|
|
CVRx Inc
Glance View
CVRx, Inc. develops proprietary active implantable technology to treat high blood pressure and heart failure. The company is headquartered in Minneapolis, Minnesota and currently employs 109 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing, manufacturing and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its platform technology offers BAROSTIM, designed to control the brain to address the imbalance of the autonomic nervous system (ANS), which causes heart failure (HF) and other cardiovascular diseases. The Company’s product, BAROSTIM NEO, is a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction (HFrEF). BAROSTIM NEO provides baroreflex activation therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. BAROSTIM NEO consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead.
See Also
What is CVRx Inc's Research & Development?
Research & Development
-11.1m
USD
Based on the financial report for Dec 31, 2025, CVRx Inc's Research & Development amounts to -11.1m USD.
What is CVRx Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-12%
Over the last year, the Research & Development growth was 0%. The average annual Research & Development growth rates for CVRx Inc have been -4% over the past three years , -12% over the past five years .
